Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Olmesartan Medoxomil Intermediates With High Quality: 4,5-Dimethyl-1,3-Dioxol-2-One (DMDO) CAS 37830-90-3 4-Chloromethyl-5-Methyl-1,3-Dioxol-2-One (DMDO-Cl) CAS 80841-78-7 Ethyl 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylate CAS 144689-93-0 Diethyl 2-Propyl-1H-Imidazole-4,5-Dicarboxylate CAS 144689-94-1 Trityl Olmesartan Ethyl Ester CAS 144690-33-5 Trityl Olmesartan Acid CAS 761404-85-7 N2-Trityl Olmesartan Acid CAS 752179-89-8 Trityl Olmesartan Medoxomil CAS 144690-92-6 Olmesartan Medoxomil CAS 144689-63-4| Item | Specifications |
| Appearance | White to Light Gray to Light Yellow Powder to Crystal |
| Purity / Analysis Method | >99.0% (GC) |
| Melting Point | 76.0~80.0℃ |
| Loss on Drying | <1.00% |
| Total Impurities | <1.00% |
| Infrared Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Olmesartan Medoxomil (CAS: 144689-63-4) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 4,5-Dimethyl-1,3-Dioxol-2-One |
| Synonyms | DMDO |
| CAS Number | 37830-90-3 |
| CAT Number | RF-PI1877 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C5H6O3 |
| Molecular Weight | 114.10 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
4,5-Dimethyl-1,3-Dioxol-2-One (DMDO) (CAS: 37830-90-3) is used in the preparation of Olmesartan Medoxomil (CAS: 144689-63-4). Olmesartan Medoxomil was launched in the US as Benicar@, an orally administered treatment for hypertension. Olmesartan, is a new selective and competitive nonpeptide angiotensin II type 1 receptor antagonist and potently inhibits the Ang.ll-induced pressor responses. The drug competitively inhibited binding of [125I1]-All to AT1 receptors in bovine adrenal cortical membranes, but had no effect on binding to AT2 receptors in bovine cerebellar membranes. In comparative clinical studies in patients with essential hypertension, Olmesartan reduced sitting cuff diastolic blood pressure significantly more than Losartan, Valdesartan and Ibesartan, while reductions in systolic blood pressure were similar for all treatments. Olmesartan Medoxomil was also shown to reduce blood pressure significantly more effectively than losartan and the ACE inhibitor captopril and as effectively as the pbloker atenolol.
